Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Crossy who wrote (5858)	3/9/2002 6:23:05 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Crossy, I've never followed SCLN, but this PR suggests that it may be worth a look: Tuesday March 5, 9:02 am Eastern Time Press Release SOURCE: SciClone Pharmaceuticals SciClone Pharmaceuticals Announces Positive Preliminary Data From Phase 3 Hepatitis B Trial in Japan SAN MATEO, Calif., March 5 /PRNewswire-FirstCall/ -- SciClone Pharmaceuticals (Nasdaq: SCLN - news) today announced positive preliminary data from its phase 3 clinical trial in Japan using ZADAXIN as a monotherapy treatment for hepatitis B. Preliminary data on approximately one-third of the 319 patients indicate that, after 6 months of therapy and 12 months of follow up, 24% demonstrated a successful interruption of viral replication, as measured by sustained seroconversion of hepatitis B e-antigen (loss of HBeAg and the development of antibody to HBeAg). By comparison, published data on lamivudine, the drug most widely used for treatment of hepatitis B worldwide, indicate that lamivudine is capable of inducing sustained HBeAg seroconversion in 16% of Asian patients that took the drug for one year. ``We are very pleased by this preliminary data from our phase 3 hepatitis B clinical trial in Japan and expect the remaining patients to complete therapy and follow up by the end of this year,'' said Eduardo Martins, Medical Director of SciClone. ``We continue to make progress towards our goal of bringing ZADAXIN to the major pharmaceutical markets of the U.S., Europe and Japan. We are on target to start enrollment for our U.S. phase 3 hepatitis C clinical trials next month.'' On Thursday, March 7, 2002, Donald R. Sellers, President and CEO of SciClone, will be presenting at the RedChip Partners(TM) Investor Conference in Boca Raton, Florida. The presentation will be webcast live starting at 11:00 am Eastern Standard Time. The webcast can be viewed live by registering at www.redchip.com or by calling 1-800-REDCHIP (1-800-733-2447). ZADAXIN has been administered without side effects to over 10,000 patients and is approved for sale in 26 countries, principally for the treatment of hepatitis B and hepatitis C, and certain cancers. ZADAXIN, an immune system enhancer (ISE), is a synthetic preparation of thymosin alpha 1, an immune system peptide that exists naturally in humans and whose activities are recognized to regulate the body's effective immune response to serious viral infections and certain cancers. There is a hype warning in the above, though: ZADAXIN has been administered without side effects to over 10,000 patients You give people a placebo and they have side effects, so that statement from the PR is undoubtedly an exaggeration. The company thread also has over 1,000 posts on SI - that's about 10X the valuation (in millions) you cite. A high posts-to-valuation ratio is never a good sign. <g> Peter